CEO
Haima Therapeutics
Cleveland, Ohio, United States
Michael Bruckman, PhD – Chief Executive Officer (CEO). Bruckman has a PhD in Organic Chemistry from the University of South Carolina and over 20 years of R&D experience in nanotechnology for various applications. Dr. Bruckman joined Haima in 2018 with several years of experience running an R&D program as Director of Research and Development at a NanoBio Systems, a spinout company from Northeastern University focused on developing saliva-based glucose sensors. He worked directly with the CEO to build a research team, develop regulatory and go-to-market strategies, support dilutive and non-dilutive fundraising, and communicate with various stakeholders. He has 26 publications, 2 book chapters, and 3 patents.
PB1053 - Therapeutic Window of a Synthetic Platelet Nanotechnology in New Zealand White Rabbits
Tuesday, June 25, 2024
13:45 – 14:45 ICT